The evolving biology and treatment of prostate cancer
J. Clin. Invest. Russel S. Taichman, et al. 117:2351 doi:10.1172/JCI31791 [Go to this article.]

Figure 2
Effect of NCCN guidelines on prostate cancer screening and detection. Screening that starts at age 50 still results in prostate cancers that metastasize prior to detection and are therefore incurable. The initiation of screening starting at age 40, factoring in PSA value and PSA velocity, has the goal of the detection of more clinically relevant cancers and should result in increased sensitivity of PSA as a screening test. The effect on specificity and whether this method will also result in an increase in non–clinically relevant cancers remains undetermined.